At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
00013 HUTCHMED
Trading 01-12 15:49:46
23.100
-0.140
-0.60%
High23.460
Low22.760
Vol5.00M
Open23.220
D1 Closing23.240
Amplitude3.01%
Mkt Cap20.14B
Tradable Cap20.14B
Total Shares872.00M
T/O115.25M
T/O Rate0.57%
Tradable Shares872.00M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Loading ...
Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Multiple Positive Catalysts Drive Five-Day Rally, Is HUTCHMED (00013) Turning Around After Missing the Bull Run?
Hong Kong Stock Concept Tracking | China's NMPA Optimizes Review and Approval Process for Clinically Urgent Overseas Drugs, Sustaining High Growth Momentum in Innovative Medicines (Including Concept Stocks)
HUTCHMED (00013) Announces Positive Top-Line Results from Phase III Stage of ESLIM-02 Study of Sovleplenib in Warm Antibody Autoimmune Hemolytic Anemia in China
HUTCHMED (00013) Initiates Phase III Stage of Ongoing Study of Surufatinib Combined with Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma
HUTCHMED Initiates Phase Iii Stage of the Ongoing Trial of the Combination of Surufatinib and Camrelizumab for Treatment-NaÏVe Pancreatic Ductal Adenocarcinoma
HUTCHMED Announces Nda Acceptance in China With Priority Review Status for Savolitinib for the Treatment of Gastric Cancer Patients With Met Amplification
HUTCHMED (China) Ltd is an investment holding company principally engaged in the manufacture and sale of pharmaceuticals. The Company operates its business through two segments. Oncology Immunology segment is engaged in the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Among it, research and development (R&D) includes research and development activities covering drug discovery, development, manufacturing and regulatory functions, out-licensing of in-house developed drugs, as well as administrative activities to support research and development operations, marketed products comprises the invoiced sales, marketing, manufacture and distribution of drugs developed from research and development activities. Other Ventures segment is engaged in the other commercial businesses which include the sales, marketing, manufacture and distribution of other prescription drugs and healthcare products.